Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Transgene
  6. Summary
    TNG   FR0005175080

TRANSGENE

(TNG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
07/20/2021 07/21/2021 07/22/2021 07/23/2021 07/26/2021 Date
2.23(c) 2.185(c) 2.19(c) 2.275(c) 2.26(c) Last
32 822 58 982 39 916 28 815 59 155 Volume
+2.53% -2.02% +0.23% +3.88% -0.66% Change
More quotes
Estimated financial data (e)
Sales 2021 11,1 M 13,1 M 13,1 M
Net income 2021 -27,0 M -31,9 M -31,9 M
Net cash position 2021 44,7 M 52,8 M 52,8 M
P/E ratio 2021 -8,07x
Yield 2021 -
Sales 2022 8,10 M 9,56 M 9,56 M
Net income 2022 -32,5 M -38,4 M -38,4 M
Net cash position 2022 12,7 M 15,0 M 15,0 M
P/E ratio 2022 -6,85x
Yield 2022 -
Capitalization 221 M 260 M 260 M
EV / Sales 2021 15,8x
EV / Sales 2022 25,7x
Nbr of Employees 139
Free-Float 51,4%
More Financials
Company
Transgene SA is a biopharmaceutical company. The Company designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The Company has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The... 
More about the company
Ratings of Transgene
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about TRANSGENE
06/28Transgene Announces Update on Phase I Clinical Trial of TG4050
CI
06/25GLOBAL MARKETS LIVE : Facebook, Toshiba, Fedex, Nike, Microsoft...
06/24Transgene announces First Patient Enrolled in Expanded Phase II Clinical Tria..
CI
06/22GLOBAL MARKETS LIVE : Netflix, Boeing, Tesla, Delta Air Lines, Blackstone Resour..
06/22TRANSGENE : Raises $40.6 Million in Share Sale; Stock Falls 7%
MT
06/22TRANSGENE : Admission of new securities
CO
06/08Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic ..
CI
05/27BioInvent, Transgene Win US FDA Nod For Phase 1/2a Study of Cancer Vaccine
MT
05/27BIOINVENT INTERNATIONAL : and Transgene receive IND approval from the U.S. FDA f..
AQ
05/27Bioinvent International AB and Transgene Receive IND Approval from the U.S. F..
CI
04/28Global markets live: Microsoft, Apple, Tesla...
04/27TRANSGENE : April 27, 2021 - Transgene reports business update and end Q1 2021 f..
PU
04/27LogicBio announces clinical and corporate updates
DJ
04/27TRANSGENE : 1st quarter earnings
CO
04/12TRANSGENE : April 12, 2021 - Transgene Announces Upcoming Investor Meetings
PU
More news
News in other languages on TRANSGENE
06/28TRANSGENE : premier patient inclus dans un essai de phase I
06/28STOCK MARKET PARIS : Le S&P500 sur son 31 avant le couperet de l'emploi
06/28TRANSGENE : 28 juin 2021 - Premier patient inclus au Royaume-Uni dans l'essai de..
06/25STOCK MARKET PARIS : Insubmersible
06/25EN DIRECT DES MARCHES : Renault, Air Liquide, EssilorLuxottica, Natixis, Vallour..
More news
Chart TRANSGENE
Duration : Period :
Transgene Technical Analysis Chart | TNG | FR0005175080 | MarketScreener
Technical analysis trends TRANSGENE
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 2,26 €
Average target price 3,80 €
Spread / Average Target 68,1%
EPS Revisions
Managers and Directors
Hedi Ben Brahim Chairman & Chief Executive Officer
Jean-Philippe Del Chief Financial Officer
Eric Quéméneur Chief Scientific Officer & Executive VP
Hemanshu Shah VP-Medical Affairs & International Development
Maud Brandely VP-Clinical Operations & Regulatory Affairs
Sector and Competitors
1st jan.Capi. (M$)
TRANSGENE37.14%268
GILEAD SCIENCES, INC.18.01%85 134
WUXI APPTEC CO., LTD.32.49%71 226
REGENERON PHARMACEUTICALS19.60%57 013
BIONTECH SE251.15%55 555
VERTEX PHARMACEUTICALS-15.83%50 308